Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia

Journal of Psychiatric Research

Volumn 44, Issue 16, 2010, Pages 1176-1189

  Martins de Souza, Daniel ^a,c   Maccarrone, Giuseppina ^a   Wobrock, Thomas ^b   Zerr, Inga ^b   Gormanns, Philipp ^a   Reckow, Stefan ^a   Falkai, Peter ^b   Schmitt, Andrea ^b,c   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarkers; CSF; Mass spectrometry; Proteomics; Schizophrenia; Thalamus

Indexed keywords

BENPERIDOL; BIOLOGICAL MARKER; CHLORPROTHIXENE; CLOPENTHIXOL; CLOZAPINE; CRYSTALLIN; FLUPENTIXOL; GLIAL FIBRILLARY ACIDIC PROTEIN; HALOPERIDOL; MU CRYSTALLIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OLANZAPINE; PERAZINE; PERPHENAZINE; PIPAMPERONE; PROMETHAZINE; PROTEIN KINASE C GAMMA; PROTEOME; PROTHIPENDYL; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TIAPRIDE; UNCLASSIFIED DRUG; VALPROIC ACID; ZOTEPINE; ZUCLOPENTHIXOL;

AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; ENERGY METABOLISM; FEMALE; GLYCOLYSIS; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MEDIODORSAL THALAMUS; MENTAL PATIENT; NEUROPATHOLOGY; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; PSYCHOPHARMACOTHERAPY; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; THALAMUS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GLUCOSE METABOLISM DISORDERS; GLYCOLYSIS; HUMANS; ISOELECTRIC FOCUSING; MALE; MASS SPECTROMETRY; MIDDLE AGED; NADP; PROTEOME; PROTEOMICS; PYRUVIC ACID; SCHIZOPHRENIA; THALAMUS; YOUNG ADULT;

EID: 77954977417     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.04.014     Document Type: Article

References (53)

1. Al-Shahrour F., Minguez P., Tárraga J., Medina I., Alloza E., Montaner D., et al. FatiGO+: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments. Nucleic Acids Research 2007, 35:W91-W96. (Web Server issue).
2. American PA Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
3. Andreasen N.C., Arndt S., Swayze V., Cizadlo T., Flaum M., O'Leary D., et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994, 266:294-298.
4. Bassett A.S., Collins E.J., Nuttall S.E., Honer W.G. Positive and negative symptoms in families with schizophrenia. Schizophrenia Research 1993, 11:9-19.
5. Ben-Shachar D., Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. International Review of Neurobiology 2004, 59:273-296.
6. 2+) connection in dopamine signaling. Trends in Pharmacological Sciences 2003, 24:486-492.
7. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica 2006, 112(4):389-404.
8. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991, 82(4):239-259.
9. Braceland F.J., Meduna L.J., Vaichulis J.A. Delayed action of insulin in schizophrenia. The American Journal of Psychiatry 1945, 102:108-110.
10. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
11. Braus D.F., Weber-Fahr W., Tost H., Ruf M., Henn F.A. Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. Archives of General Psychiatry 2002, 59:696-701.
12. Bruneau E.G., McCullumsmith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophrenia Research 2005, 75:27-34.
13. Byne W., Dracheva S., Chin B., Schmeidler J.M., Davis K.L., Haroutunian V. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei. Schizophrenia Research 2008, 98:118-128.
14. Byne W., Hazlett E.A., Buchsbaum M.S., Kemether E. The thalamus and schizophrenia: current status of research. Acta Neuropathologica 2009, 117:347-368.
15. Davis K.L., Buchsbaum M.S., Shihabuddin L., Spiegel-Cohen J., Metzger M., Frecska E., et al. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry 1998, 43:783-793.
16. de Haan L., Bakker J.M. Overview of neuropathological theories of schizophrenia: from degeneration to progressive developmental disorder. Psychopathology 2004, 37:1-7.
17. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of general psychiatry 1976, 33:766-771.
18. Frances A.J., First M.B., Widiger T.A., Miele G.M., Tilly S.M., Davis W.W., et al. An A to Z guide to DSM-IV conundrums. Journal of Abnormal Psychology 1991, 100:407-412.
19. Freedman R. Schizophrenia. The New England Journal of Medicine 2003, 349:1738-1749.
20. Gattaz W.F., Hubner C.V., Nevalainen T.J., Thuren T., Kinnunen P.K. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biological Psychiatry 1990, 28:495-501.
21. Götz S., García-Gómez J.M., Terol J., Williams T.D., Nagaraj S.H., Nueda M.J., et al. High-throughput functional annotation and data mining with the Blast2GO suite. Nucleic Acids Research 2008, 36(10):3420-3435.
22. Haydon P.G. GLIA: listening and talking to the synapse. Nature Review Neurosciences 2001, 2:185-193.
23. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994, 13:195-207.
24. Jahn T., Mussgay L. Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten. Zeitschrift für klinische Psychologie und Psychotherapie 1989, 18:257-267.
25. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
26. Kooy F.H. Hyperglycemia in mental disorders. Brain 1919, 17:214-289.
27. Lang D.J., Khorram B., Goghari V.M., Kopala L.C., Vandorpe R.A., Rui Q., et al. Reduced anterior internal capsule and thalamic volumes in first-episode psychosis. Schizophrenia Research 2006, 87:89-99.
28. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., et al. Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry 2001, 49:487-499.
29. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 1999, 46:729-739.
30. Lilliefors H. On the Kolmogorov-Smirnov test for normality with mean and variance unknown. Journal of the American Statistical Association 1967, 62:399-402.
31. Maccarrone G., Turck C.W., Martins-de-Souza D. Shotgun mass spectrometry workflow combining IEF and LC-MALDI-TOF/TOF. Protein Journal 2010, 29(2):99-102.
32. Martins-de-Souza D., Menezes de Oliveira B., dos Santos Farias A., Horiuchi R.S., Crepaldi Domingues C., de Paula E., et al. The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. Briefings in Functional Genomics & Proteomics 2007, 6:70-75.
33. Martins-de-Souza D., Oliveira B.M., Castro-Dias E., Winck F.V., Horiuchi R.S., Baldasso P.A., et al. The untiring search for the most complete proteome representation: reviewing the methods. Briefings in Functional Genomics & Proteomics 2008, 7:312-321.
34. Martins-de-Souza D. Proteomics is not only a biomarker discovery tool. Proteomics Clinical Applications 2009, 3:1136-1139.
35. Martins-de-Souza D., Gattaz W.F., Schmitt A., Rewerts C., Marangoni S., Novello J.C., et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. Journal of Neural Transmission 2009, 116:275-289.
36. Martins-de-Souza D., Gattaz W.F., Schmitt A., Novello J.C., Marangoni S., Turck C.W., et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009, 9:17.
37. Martins-de-Souza D., Gattaz W.F., Schmitt A., Maccarrone G., Hunyadi-Gulyás E., Eberlin M.N., et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. Journal of Psychiatric Research 2009, 43:978-986.
38. Martins-de-Souza D., Gattaz W.F., Schmitt A., Rewerts C., Maccarrone G., Dias-Neto E., et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. European Archives of Psychiatry and Clinical Neurosciences 2009, 259:151-163.
39. Martins-de-Souza D., Dias-Neto E., Schmitt A., Falkai P., Gormanns P., Maccarrone G., et al. Proteome analysis of schizophrenia brain tissue. The World Journal of Biological Psychiatry 2010, 11(2):110-120.
40. Martins-de-Souza D. Is the word 'biomarker' being properly used by proteomics research in neuroscience?. European Archives of Psychiatry and Clinical Neurosciences 2010, 10.1007/s00406-010-0105-2.
41. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. Journal of Psychiatric Research 2010, 44(3):149-156.
42. Meltzer H.Y., Fatemi S.H. Treatment of schizophrenia. The American psychiatric text book of psychopharmacology 1998, 127-135. American Psychiatric Press, Washington, DC. A.F. Schatzberg, C.B. Nemeroff (Eds.).
43. Min S.K., An S.K., Jon D.I., Lee J.D. Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. Psychiatry Research 1999, 90:159-168.
44. Nakatani Y., Tanioka T., Sunaga S., Murakami M., Kudo I. Identification of a cellular protein that functionally interacts with the C2 domain of cytosolic phospholipase A(2)alpha. The Journal of Biological Chemistry 2000, 275:1161-1168.
45. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry 2004, 9:684-697. 643.
46. Rodríguez-Manzaneque M.T., Ros J., Cabiscol E., Sorribas A., Herrero E. Grx5 glutaredoxin plays a central role in protection against protein oxidative damage in Saccharomyces cerevisiae. Molecular and Cellular Biology 1999, 19:8180-8190.
47. Romanski L.M., Giguere M., Bates J.F., Goldman-Rakic P.S. Topographic organization of medial pulvinar connections with the prefrontal cortex in the rhesus monkey. The Journal of Comparative Neurology 1997, 379:313-332.
48. Schmitt A., Wilczek K., Blennow K., Maras A., Jatzko A., Petroianu G., et al. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biological Psychiatry 2004, 56:41-45.
49. Steriade M., Llinás R.R. The functional states of the thalamus and the associated neuronal interplay. Physiological Reviews 1988, 68:649-742.
50. 11C]FLB 457. The International Journal of Neuropsychopharmacology 2003, 6:361-370.
51. Wilhelmus M.M., Otte-Holler I., Wesseling P., de Waal R.M., Boelens W.C., Verbeek M.M. Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathology and Applied Neurobiology 2006, 32:119-130.
52. Williamson P. Hypofrontality in schizophrenia: a review of the evidence. Canadian Journal of Psychiatry 1987, 32:399-404.
53. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry 2003, 64:663-667.